Trial · NCT05061693
Participant flow72
How many started, completed or left each group, period by period.
1 to 20 of 72
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 16-week Placebo-controlled (PC) Period | STARTED | PC Period: Placebo | 37 | |
| 16-week Placebo-controlled (PC) Period | STARTED | PC Period: Povorcitinib 15 mg | 36 | |
| 16-week Placebo-controlled (PC) Period | STARTED | PC Period: Povorcitinib 45 mg | 36 | |
| 16-week Placebo-controlled (PC) Period | STARTED | PC Period: Povorcitinib 75 mg | 37 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Placebo to Povorcitinib 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Povorcitinib 15 mg to 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Povorcitinib 45 mg to 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Povorcitinib 75 mg to 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Placebo to Povorcitinib 75 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Povorcitinib 15 mg to 75 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Povorcitinib 45 mg to 75 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | STARTED | Extension Period: Povorcitinib 75 mg to 75 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | PC Period: Placebo | 32 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | PC Period: Povorcitinib 15 mg | 29 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | PC Period: Povorcitinib 45 mg | 31 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | PC Period: Povorcitinib 75 mg | 33 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | Extension Period: Placebo to Povorcitinib 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | Extension Period: Povorcitinib 15 mg to 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | Extension Period: Povorcitinib 45 mg to 45 mg | 0 | |
| 16-week Placebo-controlled (PC) Period | COMPLETED | Extension Period: Povorcitinib 75 mg to 45 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05061693/flow